Published: January 16, 2013
Armstrong's Story Is a Sordid One
WASHINGTON, Jan. 16, 2013 /PRNewswire-iReach/ -- Lance Armstrong has finally come clean on his use of performance enhancing drugs (PEDs) in an interview with Oprah Winfrey. Now that Armstrong admitted to doping, does that help his legacy? A lot of people may still hold Armstrong in high regard, noting his work with the Livestrong Foundation for cancer research and awareness. Others will view him for noting more than a steroids cheat/liar who conned many fans for several years.
I think Lance owes A LOT of people apologies for the lies he told and the hurt he had caused people in order to keep his PED usage a secret.
So the question is again, what should Armstrong's legacy be?
To read the complete release at NewsBlaze,
Armstrong's Story Is a Sordid One,
Related PRNewswire Releases News
The Minnesota Chiropractic Association recently honored one among them for their endless dedication to public health and wellness.
On May 18 2013, The 2013 China Software Export and Service Outsourcing Conference & Release of 2012 China Software Export and Service Outsourcing Ranking List is held in Ninghai. This conference is hosted by www.csso.com.cn and Ninghai Science ...
Blue Loan Services is a full service mortgage company that rates as one of the top mortgage lenders in California and has been helping both first time and experienced homeowners to find the best refinance rates and the lowest mortgage payments for ...
Milagro Oil & Gas, Inc. , Vanquish Energy, LLC, a newly formed Delaware limited liability company to which Milagro will transfer substantially all of its assets in connection with the consummation of the Exchange Offer , and Vanquish Finance, ...
Cryptsoft Pty Ltd and ID Quantique SA, announce completion of a technology integration of a quantum entropy source within a standards compliant KMIP server, to deliver class leading key generation and management capability.
Shareholder rights attorneys at Robbins Arroyo LLP announce that a shareholder of Ventrus Biosciences, Inc. filed a federal securities fraud class action complaint on May 9, 2013, in the U.S. District Court for the Southern District of New York. ...